TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Sep 26, 2022 20:14 JST
Source:
Eisai
Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
TOKYO, Sep 26, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have obtained manufacturing and marketing approval from the Japanese Ministry of Health, Labour and Welfare for the indication of the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") for the treatment of rheumatoid arthritis. Metoject will be the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan. Based on the license agreement signed by Eisai and medac GmbH in May 2019, nippon medac will hold the marketing authorization of Metoject, while Eisai will be responsible for product distribution of Metoject in Japan.
The approval is based on the results of a Phase III clinical trial (MC-MTX.17/RA) conducted in Japan by nippon medac to compare the efficacy and safety of Metoject with that of oral MTX, which consisted of a double-blind phase and an extension phase. In the double-blind phase of this trial, 102 rheumatoid arthritis patients who had not been treated with MTX received either 7.5 mg/week of Metoject or 8 mg/week of oral MTX for 12 weeks in repeated doses. The primary endpoint of ACR20 response* at 12 weeks was 59.6% in the Metoject group versus 51.0% in the oral MTX group, indicating comparable efficacy. The adverse drug reaction incidence rates in this trial were 25.0% in the Metoject group and 34.0% in the oral MTX group. In the double-blind phase, the most common adverse drug reactions (incidence 5% and higher) were stomatitis (5.8%) in the Metoject group, and nausea (12.0%) and stomatitis (6.0%) in the oral MTX group.
It is reported that there are approximately 700,000 - 800,000 rheumatoid arthritis patients in Japan. MTX is used as the first-line option for the treatment of rheumatic arthritis, but only the oral formulation is available in Japan. Eisai and nippon medac will provide a self-administrable subcutaneous injection as a new treatment option for rheumatoid arthritis patients in Japan as soon as possible, and will make further contributions to address the diversified needs of, and increase the benefits provided to, rheumatoid arthritis patients.
*ACR20 is a criterion developed by the American College of Rheumatology that measures improvement in clinical symptoms of rheumatoid arthritis. It expresses the percentage of patients who demonstrated a 20% or greater improvement in tender and swollen joint counts and at least three of the following five disease activity variables: patient assessment of pain; patient assessment of global disease activity; physician assessment of global disease activity; patient assessment of physical function; and chronic response protein or erythrocyte sedimentation rate concentrations.
For more information, visit www.eisai.com/news/2022/news202269.html.
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
March 24 2023 12:22 JST
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
March 23 2023 12:30 JST
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
March 20 2023 10:18 JST
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
March 14 2023 10:09 JST
Eisai Receives the "Basic Achievement Grand Prize" at the 2023 J-Win Diversity Award
March 10 2023 14:04 JST
Eisai Certified as a 2023 Health and Productivity Management Outstanding
March 09 2023 08:07 JST
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
March 06 2023 09:58 JST
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan
March 02 2023 09:45 JST
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
February 28 2023 14:28 JST
Dissolution of Bracco-Eisai Joint Venture
February 21 2023 13:02 JST
More Press release >>
Latest Press Release
DENSO Wins Silver Medal at the 10th International Abilympics
Mar 27, 2023 19:37 JST
Hitachi Continuously Selected as CDP Supplier Engagement Leader
Mar 27, 2023 18:52 JST
Educational Manga Prepared as Teaching Tool for school child: "The Secrets of SDGs - Affordable and Clean Energy"
Mar 27, 2023 15:21 JST
Mazda: Conclusion of offsite corporate power purchase agreement (PPA) on solar power generation
Mar 27, 2023 14:52 JST
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
Mar 24, 2023 13:22 JST
Mitsubishi Corporation: PoC Launched in Portland, Oregon to Develop Smart Multifamily Apartment
Mar 24, 2023 11:02 JST
MHI and PLN Nusantara Power to Investigate Co-Firing with Hydrogen, Ammonia and Biomass in Indonesia's Power Plants
Mar 24, 2023 10:26 JST
MHI Thermal Systems to Launch 22 Models of Residential-use Room Air Conditioners for the Japanese Market in 2023 (Domestic sales only)
Mar 24, 2023 10:17 JST
Fujitsu Announces Start of Acceptance Period of Takeover Offer for GK Software
Mar 23, 2023 20:28 JST
The Hitachi Group has started a strategic cooperation with the leading operator of non-cash payments Polskie ePlatnosci in the development of software and IT systems
Mar 23, 2023 18:10 JST
Eisai to Present New Lecanemab Data, Including Research Evaluating Safety Profile, Clinical Outcomes and Quality of Life Measures, as Well as Other Important Alzheimer's Disease Research, at the AD/PD 2023 Annual Meeting
Mar 23, 2023 13:30 JST
Fujitsu and Osaka University develop new quantum computing architecture, accelerating progress toward practical application of quantum computers
Mar 23, 2023 11:14 JST
Fujitsu named a "Nadeshiko Brand" company for promoting women's success
Mar 22, 2023 16:45 JST
Mitsubishi XRT Concept to Debut at Bangkok International Motor Show 2023
Mar 21, 2023 15:00 JST
Toyota Launches the C+walk S in Japan, a New Form of Walking-Assistance Mobility
Mar 20, 2023 18:00 JST
Another record win for Ogier aboard the GR YARIS Rally1 HYBRID
Mar 20, 2023 14:41 JST
TOYOTA GAZOO Racing secures Sebring one-two
Mar 20, 2023 14:25 JST
Eisai Publishes Societal Value of Lecanemab Using Phase 3 Clarity AD Data in Peer-Reviewed Neurology and Therapy Journal
Mar 20, 2023 11:18 JST
Liquid Hydrogen-Powered Corolla to be Absent from Round 1 of the Super Taikyu Series at Suzuka Development to Continue for Fuji 24 Hours Race
Mar 20, 2023 09:48 JST
Mitsubishi Heavy Industries Power IDS to Upgrade Steam Turbine Generators at Incineration Plant in Taiwan
Mar 17, 2023 22:35 JST
More Latest Release >>